



FOR IMMEDIATE RELEASE

Press Release Date:

Friday 15-Apr-2016

Ottawa, Ontario, Canada

ICAHRIS and NYCNMR reach a new summit on nano-innovation.

A strategic partnering agreement focusing on sentinel nanotechnologies for early disease prevention

Contact:

Dr Gabriel Pulido-Cejudo
CEO
BioConverGene
Technologies Corporation

gabriel.pulido-cejudo@icahris.org

www.icahris.org

1-5380 Canotek Road
Ottawa, ON K1J 1H7
(613) 276-5679

The International Centre for Advancement of Health Regional Innovation and Science (ICAHRIS) and the New York Center for Nanomedicine Research (NYCNMR) have secured a substantial competitive advantage in the emerging field of nanomedicine. Early this morning, ICAHRIS and NYCNMR signed a strategic agreement at the BioConverGene Accelerator in the Canotek Industrial Park in Eastern Ottawa. Focusing on the development and deployment of non-invasive sentinel nanotechnologies for the early detection and treatment of pressing diseases such as cancer and type 2 diabetes, this partnering agreement also supports research on women's and maternal-infant health. Furthermore, the agreement targets the development of technologies that can help individuals who are potentially affected by obesity-related conditions, such as type 2 diabetes and abnormal inflammatory processes which could lead to various types of cancers, among other ailments. One of the most daring aspects of this partnering agreement is its emphasis on immediate early disease prevention. After two years of developing and testing protocols, ICAHRIS was also pleased to announce the release of the **first generation of iBioSign's Health Profile Navigator™ (HPN™)**. The Health Profile Navigator™ is an intuitive, interactive and correlational tool that provides individuals (end-users) with the ability to securely compile their health profiles in one single place. It also offers end-users the option of exploring innovative ways to interact with emerging health technologies, such as sentinel nanotechnologies aimed at providing effective disease prevention. During the public announcement, Dr Gabriel Pulido-Cejudo, Chairman of ICAHRIS, **provided concrete examples of BioConverGene's** upcoming sentinel nanotechnologies and their applications to better assess, for example, the early onset of metabolic changes that could signal initial stages of depression during and / or after pregnancy. This is an important mental health concern affecting up to 16 per cent of pregnant women in North America. Dr Pulido emphatically underlined the importance of securing a strategic partnering with NYCNMR. Co-founded by Scottpatrick J. Sellitto, a prolific inventor and reputable industrious scientist, NYCNMR possesses robust infrastructure and an array of comprehensive technology in the field of nanomedicine research. NYCNMR joins ICAHRIS at an important juncture. In addition to on-going collaborations with scientists and entrepreneurs in Canada, Mexico and the United States, ICAHRIS and NYCNMR will press on into the next level of technology miniaturization and scientific innovation in the field of sentinel nanotechnologies, with a focus on human health. With close to 1.2 million dollars privately raised by R&D companies currently aligned with ICAHRIS' international partnering initiatives, including BioConverGene Technologies Corporation, ICAHRIS remains optimistic about the current spirited tone of both the Federal and Provincial governments to tangibly support Canadian entrepreneurial innovation towards achieving global competitiveness.

-ENDS-